Long-term cure rates for multidrug-resistant tuberculosis much better than expected

A new national cohort study provides important insights into the treatment of multidrug-resistant tuberculosis (MDR-TB). The study shows that long-term disease-free survival rates are significantly higher than previous standard indicators suggest. The results, published in The Lancet Regional Health Europe, are based on the analysis of data from 1,299 adult patients treated between 2005 and 2021. The study was in collaboration with researchers from the clinical tuberculosis infrastructure (ClinTB) at the German Center for Infection Research (DZIF) at the Research Center Borstel, Leibniz Lung Center (FZB).